PCSK9 gene silencing therapy for LDL cholesterol

there are no large, peer‑reviewed human outcome trials yet, and real‑world questions remain (delivery to the liver, durability, off‑target effects, immune reactions, cost). So, this is promising but experimental. Current best approach for high LDL—especially in South Asians—is proven therapy: lifestyle + statins as foundation, adding ezetimibe or approved PCSK9 inhibitors if needed to reach targets.